BACKGROUND: Gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF) and may contribute to its progression. Anti-acid therapy, such as proton pump inhibitors (PPIs), has been considered as a potential treatment option for IPF. The evidence for this treatment comes from several observational studies affected by time-related bias.
RESEARCH QUESTION: Is use of PPIs in patients with IPF associated with a reduction in all-cause mortality, respiratory-related mortality, and respiratory-related hospitalization? STUDY DESIGN AND METHODS: We used the UK Clinical Practice Research Datalink to identify a cohort of patients diagnosed with IPF between 2003 and 2016. The prevalent new-user cohort design was used to match patients initiating PPIs with non-users using time-conditional propensity scores, with follow-up until death or end of observation. Cox models were used to estimate hazard ratios (HR) and 95% CIs of death and of a respiratory-related hospitalization, correcting for informative censoring by weighted inverse probability.
RESULTS: There were 1,852 PPI users who were matched to 1,852 non-users identified among the cohort of patients with IPF, with 2.8 years' median survival (mortality rate, 26.7 per 100 per year). The HR of all-cause mortality with PPI use was 1.07 (95% CI, 0.94-1.22), relative to non-use. For respiratory-related mortality, the HR was 1.10 (95% CI, 0.94-1.28) and 1.00 (95% CI, 0.86-1.16) for respiratory-related hospitalizations.
INTERPRETATION: PPI use was not associated with lower mortality or hospitalization incidence in this large study conducted among patients with IPF within a real-world setting of clinical practice and designed to avoid biases affecting previous studies. PPIs may not be as beneficial in treating IPF as suggested by some studies and conditionally recommended in treatment guidelines.
|組織名||Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, QC, Canada; Centre for Clinical Epidemiology, Lady Davis;Institute, Jewish General Hospital, Montreal, QC, Canada.;Department of Medicine, McGill University, Montreal, QC, Canada.;Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, QC, Canada; Division of Respiratory Medicine, Jewish General Hospital,;Montreal, QC, Canada.;Institute, Jewish General Hospital, Montreal, QC, Canada. Electronic address:;firstname.lastname@example.org.|